Skip to main content
Bethan Cracknell Daniels on Muck Rack

Bethan Cracknell Daniels

As seen in: Nature, PLOS, BioRxiv, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bethan Cracknell

Contact Bethan Cracknell, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early individualized risk prediction using clinical data for children during the febrile phase of dengue in outpatient settings in Vietnam and Thailand

|
By Sorawat Sangkaew, Bethan Cracknell Daniels, Damien K. Ming, Bernard Hernandez
| PLOS
Loading metrics Open Access Peer-reviewed Research Article Citation: Sangkaew S, Daniels BC, Ming DK, Hernandez B, Herrero P, Suntarattiwong P, et al. (2026) Early individualized risk prediction using clinical data for children during the febrile phase of dengue in outpatient settings in Vietnam and Thailand. PLOS Digit Health 5(2): e0001171.
Open in Who Shared Issue with article?

Characterising the benefits and risks of vaccines approved through accelerated pathways

|
By Bethan Cracknell Daniels, Joseph Lewnard, Oscar Cortes-Azuero, Tim Endy
| medRxiv
HS and OCA are consultants for Valneva in respect of phase IV trial design. HS has been a consultant for Gavi Alliance; HS and BCD are consultants for CEPI. TE, JLDF, JGB, AP, RC, NL are paid employees of CEPI. CEPI has supported the technology transfer of IXCHIQ to Institut Butantan in Brazil. We acknowledge funding from the Coalition of Epidemic Preparedness Innovation (CEPI) (HS, BCD). TE, JLDF, JGB, AP, R, NL are paid employees of CEPI.
Open in Who Shared Issue with article?

Efficacy, public health impact and optimal use of the Takeda dengue vaccine

|
By Bethan Cracknell Daniels, Neil Ferguson, Ilaria Dorigatti
| medRxiv
The authors have declared no competing interest. ID acknowledges funding from Wellcome Trust (213494/Z/18/Z). NMF, BCD and ID acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking.
Open in Who Shared View Duplicates (48) Issue with article?
See all 5 articles